Bridgeway Inc.

Bridgeway Inc. is a United States-based medical entity that was targeted in a significant cyberattack. On March 11, 2021, the organization was compromised by the Pysa threat actor group, which deployed Mespinoza ransomware to infiltrate its systems. This attack led to the exfiltration and encryption of sensitive patient data, including Social Security numbers and medical histories. The perpetrators maintained a dark web leak site as part of their extortion strategy, using the threat of public data exposure to pressure victims into paying ransoms. Despite clear evidence that medical data had been exposed, Bridgeway did not issue any public notifications or disclosures concerning the incident. The breach was part of a coordinated campaign affecting multiple U.S. medical organizations, where several impacted entities chose to publicly disclose the compromises and report patient impacts to regulators. Bridgeway's decision to remain silent aligned with a documented pattern of unreported compromises within the healthcare sector linked to the Pysa group, indicating a broader issue of nondisclosure following such attacks.

The Pysa group's methodology combined data theft with encryption, leveraging the sensitivity of healthcare information to maximize leverage over victims. In the healthcare sector, breaches of this nature typically invoke mandatory regulatory reporting obligations due to the protected health information involved. Bridgeway's failure to disclose the incident, despite the exfiltration of highly personal data, highlights persistent challenges in transparency and accountability within the industry. This behavior contributes to a landscape where patients may remain unaware their information was compromised, potentially hindering their ability to take protective measures. The incident underscores the particular vulnerability of medical entities to ransomware operations and the divergent approaches organizations take in the aftermath of a security event. While some entities prioritize public communication and regulatory compliance, others, like Bridgeway in this instance, opt for nondisclosure, reflecting varied strategic or reputational considerations in breach response. The long-term implications of such choices for patient trust and sector-wide security practices remain a concern, though specific repercussions for Bridgeway are not detailed in the available information.